Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stocks Crossing The 13 Week Moving Average <$10.01 -- Ignore unavailable to you. Want to Upgrade?

To: Bucky Katt who wrote (11419)	8/7/2002 11:01:56 AM
From: xcr600	Read Replies (2) \| Respond to of 13094

08:22 ET Solly examines stock option expensing for biotech : Salomon Smith Barney says that the U.S. biotech industry is likely to have a greater earnings adjustment impact from expensing stock options than the S&P 500 and S&P 100; firm estimates that expensing stock options would have had a negative impact to EPS in 2001 for the following co's: MEDI (-54.4%), IDPH (-42.4%), DNA (-36.8%), BGEN (-16.3%), and AMGN (-14.4%).